The “Cardiovascular Outcomes in Participants with Type 2 Diabetes Mellitus” study, which compares CV outcomes of several drug classes (SGLT-2 inhibitors, GLP-1 RAs, DPP-4 inhibitors, Thiazolidinedione, Sulfonylureas and Insulin) could give further insight into this question. Here, SLC5A2 is linked to diabetes mellitus.